AVANDIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AVANDIA (AVANDIA).
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver.
| Metabolism | Extensively metabolized via CYP2C8; minimal contribution from CYP2C9. |
| Excretion | Primarily hepatic metabolism via CYP2C8, with minimal renal excretion of unchanged drug (<1%). Approximately 64% of the dose is excreted in urine as metabolites and 23% in feces as metabolites. |
| Half-life | 3-4 hours (terminal elimination half-life). No clinically significant accumulation with once-daily dosing. |
| Protein binding | 99.8% bound primarily to serum albumin. |
| Volume of Distribution | 0.29 L/kg (approximately 20 L for a 70 kg individual). Indicates distribution mainly into extracellular fluid. |
| Bioavailability | Absolute bioavailability of oral rosiglitazone is 99% (nearly complete absorption). Food does not affect the area under the curve (AUC), but delays peak concentration. |
| Onset of Action | Oral: Reduction in fasting plasma glucose is observed within 2 weeks, but maximal glycemic effects may take 6–12 weeks. |
| Duration of Action | 24 hours (supports once-daily dosing). Blood glucose lowering persists throughout the day with once-daily administration. |
| Action Class | Thiazolidinedione(PPAR gamma agonist) |
| Brand Substitutes | Rositus 4mg Tablet, Rosigon 4mg Tablet, Reglit 4mg Tablet, Senzia 4mg Tablet, Rosinorm 4mg Tablet |
Initial dose 4 mg orally once daily; may increase to 8 mg once daily or 4 mg twice daily if inadequate glycemic control after 8-12 weeks. Maximum dose 8 mg/day.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended for use in severe renal impairment (CrCl <30 mL/min) or dialysis patients due to lack of data. |
| Liver impairment | Contraindicated in patients with Child-Pugh Class B or C hepatic impairment. Use with caution in Child-Pugh Class A; monitor liver enzymes. Initiate at 4 mg once daily. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment required; monitor for fluid retention and heart failure. Use lowest effective dose (4 mg/day) due to increased risk of edema and hypoglycemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AVANDIA (AVANDIA).
| Breastfeeding | Excretion into human milk unknown; M/P ratio not available. Not recommended during breastfeeding due to potential for infant hypoglycemia and lack of safety data. |
| Teratogenic Risk | Teratogenic risk in first trimester: No evidence of increased risk of major congenital anomalies, but limited data. Second and third trimesters: Risk of fetal growth restriction, hypoglycemia, and respiratory distress due to macrosomia; AVANDIA may increase maternal weight gain and risk of large-for-gestational-age infants. Avoid use in pregnancy if possible. |
■ FDA Black Box Warning
May cause or exacerbate congestive heart failure. Not recommended in patients with symptomatic heart failure. Fluid retention leading to or worsening heart failure.
| Serious Effects |
["New York Heart Association (NYHA) Class III or IV heart failure","Known hypersensitivity to rosiglitazone or any component of the formulation"]
| Precautions | ["Fluid retention and heart failure","Edema","Weight gain","Hepatic effects (elevated liver enzymes)","Ovulation in premenopausal anovulatory women leading to pregnancy risk","Macular edema","Fractures in female patients"] |
| Food/Dietary | No specific food interactions, but alcohol consumption should be minimized as it can cause hypoglycemia or hyperglycemia unpredictably. Grapefruit juice does not significantly interact. Advise consistent meal timing and carbohydrate intake to optimize glycemic control. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose levels and HbA1c; fetal growth via ultrasound (risk of macrosomia and growth abnormalities); signs of maternal fluid retention (peripheral edema) and hepatic function; neonatal blood glucose monitoring for hypoglycemia if used near delivery. |
| Fertility Effects | May improve ovulatory function in women with polycystic ovary syndrome (PCOS) by reducing insulin resistance, potentially increasing fertility. No adverse effects on fertility reported. |
| Clinical Pearls | Avandia (rosiglitazone) is associated with increased risk of cardiovascular events, including myocardial infarction and heart failure. Avoid use in patients with NYHA Class III/IV heart failure. Monitor liver function tests before and periodically during therapy due to risk of hepatotoxicity. Not recommended for use with insulin due to increased risk of fluid retention and heart failure. Consider alternative therapies in patients with preexisting cardiovascular disease. |
| Patient Advice | Take Avandia exactly as prescribed, usually once or twice daily with meals. · Do not stop taking this medication without consulting your doctor, as blood sugar levels may rise. · Watch for symptoms of fluid retention (swelling of ankles/feet, rapid weight gain) and report to your doctor immediately. · Report any signs of liver problems (nausea, vomiting, abdominal pain, dark urine, yellowing skin/eyes) promptly. · Avandia may increase risk of heart attack or heart failure; seek emergency care for chest pain, shortness of breath, or leg swelling. · Avoid alcohol consumption as it can affect blood sugar control and increase liver injury risk. · Maintain regular monitoring of blood sugar, HbA1c, and liver function tests as directed. · Inform all healthcare providers that you are taking Avandia, especially before surgery or any new medical treatment. |